NASDAQ$MLAB
Mesa Laboratories Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Mesa Labs reported an increase in revenues and operating income, but a decrease in net income.
Mesa Labs reported an 8% increase in revenues and a significant increase in operating income for the third quarter of FY21. However, net income decreased slightly compared to the same quarter in the prior year. The company highlighted strong performance in its Sterilization and Disinfection Control division and the impact of currency exchange rates on the Biopharmaceutical Development division.
- Revenues increased by 8% compared to the prior year.
- Operating income increased significantly, by 101% compared to the prior year.
- Net loss decreased by 1% compared to the same quarter in the prior year.
- Sterilization and Disinfection Control division showed strong revenue growth of 13%.
Headline financials
Revenue & EPS history
Mesa Labs · Revenue · Quarterly
$34.2M
Revenue by segment
Mesa Labs · $21.7M total across 2 segments · Q3 2021
- Sterilization and Disinfection Control$13M+10.9%59.9%
- Biopharmaceutical Development$8.71M+52.9%40.1%
Forward guidance
Mesa Labs anticipates a positive impact from mass vaccination efforts and expects continued economic recovery, while remaining prepared for potential stalls or delays. With strong cash flow and over $250 million in cash, the company is positioned for further organic and inorganic growth investments.
Tailwinds
- Positive impact of mass vaccination in the coming quarters on both the health of humanity and our business.
- Positively biased toward continued economic recovery.
- Strong positive cash flow.
- Over $250 million in cash on the balance sheet.
- Well positioned to invest for further growth both inorganically and organically.
Headwinds
- Ongoing COVID-19 headwinds.
- Potential stall or delay in economic recovery.
- Impact of COVID-19 on the ability to service customers and complete system installations.
- Strengthening of the SEK to the U.S. Dollar increased both cost of revenues and operating expenses incurred primarily in Sweden.
- Full biopharma lab reopenings stalled during the quarter with an estimated 40% of global labs still operating at reduced capacity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-0.1%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.1%
Avg return
30 days after
54%
35 / 65 earnings
Positive
+26.6%
Q2 2023
Best reaction
-24.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -15.0% | -1.3% | — | |
| Q3 2026 | +8.7% | +15.9% | +8.8% | |
| Q2 2026 | +2.1% | +6.7% | +3.7% | |
| Q1 2026 | -24.9% | -16.0% | -15.9% | |
| Q4 2025 | -9.3% | -13.5% | -12.8% | |
| Q3 2025 | +2.5% | +10.3% | +3.2% | |
| Q2 2025 | -11.4% | -16.2% | -7.6% | |
| Q1 2025 | +5.8% | +11.8% | +13.4% | |
| Q4 2024 | +13.3% | +5.5% | -3.4% | |
| Q3 2024 | +2.0% | -0.2% | +18.9% | |
| Q2 2024 | +0.1% | -8.8% | +2.0% | |
| Q1 2024 | +8.0% | +10.3% | +11.4% | |
| Q4 2023 | -2.2% | -7.7% | -11.7% | |
| Q3 2023 | -7.4% | -8.6% | -13.5% | |
| Q2 2023 | +26.6% | +31.2% | +39.1% | |
| Q1 2023 | -5.5% | -10.7% | -23.5% | |
| Q4 2022 | -3.7% | -2.7% | -6.1% | |
| Q3 2022 | -3.9% | -2.0% | -5.8% | |
| Q2 2022 | +4.0% | +1.4% | -0.1% | |
| Q1 2022 | +0.4% | -1.4% | -3.8% | |
| Q4 2021 | +4.7% | +6.4% | +9.6% | |
| Q3 2021 | +0.9% | -0.4% | -5.2% | |
| Q2 2021 | -0.4% | +2.7% | +2.1% | |
| Q1 2021 | +2.0% | -1.5% | -1.4% | |
| Q4 2020 | -5.7% | -6.5% | -18.6% | |
| Q3 2020 | -7.2% | -2.4% | -13.9% | |
| Q2 2020 | -0.2% | -4.7% | +3.3% | |
| Q1 2020 | +6.6% | +7.0% | -7.3% | |
| Q4 2019 | -21.1% | -19.3% | -2.3% | |
| Q3 2019 | +0.6% | +3.4% | +2.2% | |
| Q2 2019 | +0.9% | +3.0% | +20.4% | |
| Q1 2019 | -2.7% | -0.3% | +3.5% | |
| Q4 2018 | +16.3% | +15.4% | +31.3% | |
| Q3 2018 | -5.1% | -14.2% | -8.0% | |
| Q2 2018 | -17.2% | -19.7% | -19.7% | |
| Q1 2018 | +5.2% | +1.6% | -2.5% | |
| Q4 2017 | -6.5% | -13.3% | -12.3% | |
| Q3 2017 | +6.4% | +1.4% | +5.2% | |
| Q2 2017 | -1.3% | -0.8% | -1.1% | |
| Q1 2017 | -4.3% | -10.4% | -10.5% | |
| Q4 2016 | +12.7% | +26.5% | +23.1% | |
| Q3 2016 | -4.8% | — | — | |
| Q2 2016 | +1.9% | — | — | |
| Q1 2016 | +13.3% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | +0.8% | — | — | |
| Q2 2015 | +10.4% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -4.0% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q3 2014 | -0.2% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | -3.5% | — | — | |
| Q4 2013 | -0.2% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2011 | +1.5% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2010 | +0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro